方法：回顾性分析2015-05/2016-06在我院治疗的白内障患者的临床资料，根据其治疗方式分为普拉洛芬治疗组和普拉洛芬联合妥布霉素地塞米松滴眼液组(联合治疗组)。观察两组患者治疗前后视力、前房闪辉变化、满意率和症状体征评分的情况。

结果：两组患者治疗前视力差异无统计学意义(P>0.05)，治疗后1wk和1mo时，两组患者的视力均较治疗前明显改善，两组间比较差异无统计学意义(P>0.05)； 两组患者治疗前前房闪辉差异无统计学意义(P>0.05)，治疗后1wk和1mo时，联合治疗组的前房闪辉较普拉洛芬组低，差异有统计学意义(t=2.435、1.864，P<0.05)； 两组患者治疗前症状体征积分差异无统计学意义(P>0.05)，治疗后1wk和1mo时，联合治疗组的症状体征积分明显低于普拉洛芬组(t=2.586、7.820，P<0.05)； 联合治疗组患者治疗满意率为100%，明显高于普拉洛芬组。

结论：普拉洛芬联合妥布霉素地塞米松滴眼液在白内障摘除和后房型人工晶状体植入术后有较好的应用效果，可明显改善患者的症状体征。

METHODS: Retrospective analysis of the clinical data of cataract patients treated from May 2015 to June 2016 in our hospital. According to the treatment methods, patients were divided into tobramycin and dexamethasone ophthalmic suspension with pranoprofen group(combined treatment group)and pranoprofen treatment group. The difference of visual acuity, intraocular pressure, anterior chamber flash change, satisfaction rate and symptom score before and after treatment in two groups were observed.

RESULTS: The vision of the two groups before treatment had no difference(P>0.05). At 1wk and 1mo after treatment, the visual acuity of the two groups all improved compared with before treatment, there was no significant difference between the two groups(P>0.05). Before treatment, the anterior chamber flare of the two groups had no difference(P>0.05). At 1wk and 1mo after treatment, the anterior chamber flare of combined treatment group was lower, the difference was statistically different(t=2.435, 1.864; P<0.05). The symptom score of the two groups before treatment had no difference(P>0.05). After treatment, the symptoms and signs of combined treatment group was significantly lower than that of pranoprofen group(t=2.586, 7.820; P<0.05). The satisfaction rate of the combined treatment group patients was 100%, significantly higher than pranoprofen group.

CONCLUSION: Pranoprofen and tobradex in the treatment of cataract extraction and intraocular lens implantation has good application effect, can significantly improve the patient's symptoms and signs.